ArticleHaematologica2012

RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Sylvia Snauwaert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.